Brown CN, Chao FY, Quang D, Rumian NL, Kleinjan MS, Coultrap SJ, Bayer KU. Aß impairs the LTP-related movement of endogenous CaMKII but not of exogenous GFP-CaMKII. Mol Biol Cell. 2025 May 1;36(5):ar60. PubMed PMID: 40137857
Brown CN, Blaine RE, Barker CM, Coultrap SJ, Bayer KU. The neuroprotective ?-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIa autophosphorylation at T286 or binding to GluN2B. Mol Pharmacol. 2025 Apr;107(4):100029. PubMed PMID: 40184780
Brown CN, Barker CM, Miller CN, Aoto J, Coultrap SJ, Bayer KU. CaMKII monomers are sufficient for GluN2B binding, co-condensation, and synaptic potentiation. bioRxiv. 2025 Jul 4. PubMed PMID: 40631338
Larsen ME, Barker CM, Vargas RS, Coultrap SJ, Bayer KU. The CaMKII D135N mutation blocks kinase activity and reduces GluN2B binding. bioRxiv. 2025 Sep 21. PubMed PMID: 41000711
Tullis, J. E., Larsen, M. E., Rumian, N. L., Freund, R. K., Boxer, E. E., Brown, C. N., Coultrap, S. J., Schulman, H., Aoto, J., Dell’Acqua, M. L., and Bayer, K. U. (2023) LTP induction by structural rather than enzymatic functions of CaMKII. Nature 621(7977): 146-153.
Rumian, N. L., Freund, R. K., Dell’Acqua, M. L., Coultrap, S. J., and Bayer, K.U. (2023) Synaptic and behavioral impairments seen in aging are caused by CaMKII hypo-nitrosylation/oxidation. Science Signaling. 16(795): eade5892.
